CA2201519A1 - Preparations de complexes peptide/systeme majeur d'histocompatibilite - Google Patents

Preparations de complexes peptide/systeme majeur d'histocompatibilite

Info

Publication number
CA2201519A1
CA2201519A1 CA002201519A CA2201519A CA2201519A1 CA 2201519 A1 CA2201519 A1 CA 2201519A1 CA 002201519 A CA002201519 A CA 002201519A CA 2201519 A CA2201519 A CA 2201519A CA 2201519 A1 CA2201519 A1 CA 2201519A1
Authority
CA
Canada
Prior art keywords
peptide
mbp
mhc
complexes
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002201519A
Other languages
English (en)
Inventor
Prabha V. Mukku
Bishwajit Nag
Jeffrey L. Winkelhake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anergen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2201519A1 publication Critical patent/CA2201519A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés pour préparer des complexes peptide/système majeur d'histocompatibilité ayant une composition définie. Le peptides sont utilisés en fort excès molaire. On peut également optimiser le pH de préparation.
CA002201519A 1994-09-30 1995-09-29 Preparations de complexes peptide/systeme majeur d'histocompatibilite Abandoned CA2201519A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31553994A 1994-09-30 1994-09-30
US08/315,539 1994-09-30

Publications (1)

Publication Number Publication Date
CA2201519A1 true CA2201519A1 (fr) 1996-04-11

Family

ID=23224886

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002201519A Abandoned CA2201519A1 (fr) 1994-09-30 1995-09-29 Preparations de complexes peptide/systeme majeur d'histocompatibilite

Country Status (6)

Country Link
EP (1) EP0792157A4 (fr)
JP (1) JPH10509693A (fr)
KR (1) KR970706014A (fr)
AU (1) AU3887495A (fr)
CA (1) CA2201519A1 (fr)
WO (1) WO1996010415A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
KR970706014A (ko) * 1994-09-30 1997-11-03 슈리캔트 데슈팬드 엠에이치씨-펩티드 복합체의 제조 방법(preparation of mhc-peptide complexes)
EP1379644A2 (fr) * 2001-04-05 2004-01-14 Nextgen Sciences Ltd Analyse de proteines au moyen d'antigenes ou anticorps immobilises en reseaux

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
JP3926839B2 (ja) * 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
KR970706014A (ko) * 1994-09-30 1997-11-03 슈리캔트 데슈팬드 엠에이치씨-펩티드 복합체의 제조 방법(preparation of mhc-peptide complexes)

Also Published As

Publication number Publication date
AU3887495A (en) 1996-04-26
EP0792157A4 (fr) 1999-12-01
JPH10509693A (ja) 1998-09-22
WO1996010415A1 (fr) 1996-04-11
EP0792157A1 (fr) 1997-09-03
KR970706014A (ko) 1997-11-03

Similar Documents

Publication Publication Date Title
US5763585A (en) Method of making MHC-peptide complexes using metal chelate affinity chromatography
US6106840A (en) MHC conjugates useful in ameliorating autoimmunity
JP3487849B2 (ja) 自己免疫性を改善せしめるうえで有用なｍｈｃコンジュゲート
US5468481A (en) MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5284935A (en) MHC-mediated toxic conjugates useful in ameliorating autoimmunity
US5734023A (en) MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5824315A (en) Binding affinity of antigenic peptides for MHC molecules
CA1340012C (fr) Determinant peptidique associe a l'immunite
JP3755894B2 (ja) 自己免疫疾患の免疫療法に用いるための、自己抗原から誘導された新規なペプチド
EP0661985B1 (fr) Peptides capables de se lier aux molecules cd8 sur les precurseurs de ctl
AU2013207489A1 (en) Partial MHC constructs and methods of use
JPH11507914A (ja) Ｍｈｃ−ペプチド複合体の安定な処方物
AU670024B2 (en) Methods of treating or preventing autoimmune uveoretinitis in mammals
WO2003072598A2 (fr) Peptides derives de hsp70 et utilisations de ceux-ci dans le diagnostic et le traitement de maladies auto-immunes
EP0630255A1 (fr) Conjugues cmh permettant de traiter l'auto-immunite
WO1993009810A1 (fr) Conjugues d'une subunite du complexe majeur d'histocompatibilite utiles pour ameliorer les reponses immunitaires deleteres
CA2223714A1 (fr) Vaccination par peptides de molecules du cmh de classe ii destinee au traitement de maladie auto-immune
CA2201519A1 (fr) Preparations de complexes peptide/systeme majeur d'histocompatibilite
WO1996010415A9 (fr) Preparations de complexes peptide/systeme majeur d'histocompatibilite
EP0544862B1 (fr) Méthodes et compositions pour la prophylaxie, le diagnostic et le traitement des inflammations séreuses et des troubles associés
US20230414732A1 (en) Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use
Matsoukas et al. Designing peptide mimetics for the treatment of multiple sclerosis
JP2002521387A (ja) 共重合体１および関連する共重合体ならびにペプチドによる自己免疫疾患の治療

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead